US 12,404,494 B2
Prevention of recurrent miscarriages through administration of fibroblasts and fibroblast-educated paternal cells
Pete O'Heeron, Houston, TX (US); and Thomas Ichim, San Diego, CA (US)
Assigned to SPINALCYTE, LLC, Houston, TX (US)
Appl. No. 17/754,812
Filed by SPINALCYTE LLC, Houston, TX (US)
PCT Filed Oct. 14, 2020, PCT No. PCT/US2020/055642
§ 371(c)(1), (2) Date Apr. 13, 2022,
PCT Pub. No. WO2021/076675, PCT Pub. Date Apr. 22, 2021.
Claims priority of provisional application 62/915,292, filed on Oct. 15, 2019.
Prior Publication US 2023/0167410 A1, Jun. 1, 2023
Int. Cl. C12N 5/077 (2010.01); A61P 15/06 (2006.01); C12N 5/0783 (2010.01)
CPC C12N 5/0656 (2013.01) [A61P 15/06 (2018.01); C12N 5/0636 (2013.01); C12N 2501/10 (2013.01); C12N 2501/20 (2013.01); C12N 2501/22 (2013.01); C12N 2501/40 (2013.01)] 22 Claims
OG exemplary drawing
 
1. A method of preventing spontaneous miscarriage in an individual, the method comprising providing to the individual an effective amount of fibroblasts.